Yeji
FDA approvaloutcome: successconf 1.00

revuforj — FDA approval

$SNDX · Syndax Pharmaceuticals Inc
Event date
November 15, 2024
568 days ago
Sponsor runway
21 mo
$352.1M liquid

Evidence

“openFDA ORIG (TYPE 1) approval of REVUFORJ — application NDA218944”
Source ↗

Comparable historical fda approvals· last 5 years · same event type

100% hit rate (10/10)
TickerDrugDateOutcome
$INCYzynyz2026-05-18success
$INCYjakafi xr2026-05-01success
$AXSMauvelity2026-04-30success
$INCYzynyz2026-03-30success
$BIIBspinraza2026-03-27success
$CORTlifyorli2026-03-25success
$RYTMimcivree2026-03-19success
$ASNDyuviwel2026-02-27success
$BMRNpalynziq2026-02-27success
$ETONdesmoda2026-02-25success

Recent insider activity· ±90 days

10 insiders · 0 buys · 3 sells
Sell
2025-02-10
Metzger Michael A
Chief Executive Officer
13,288 @ $15.50$206K
Sell
2025-02-10
Gallagher Neil
President, Head of R&D
4,618 @ $15.50$72K
Sell
2025-02-10
Goldan Keith A.
Chief Financial Officer
3,777 @ $15.50$59K
Grant
2025-02-05
Metzger Michael A
Chief Executive Officer
364,000 @ $14.65$5.33M
Grant
2025-02-05
Meury William
Director
25,000 @ ——
Grant
2025-02-05
Legault Pierre
Director
25,000 @ ——
Grant
2025-02-05
Podlesak Dennis
Director
50,000 @ ——
Grant
2025-02-05
Jarrett Jennifer
Director
25,000 @ ——
Grant
2025-02-05
Rizo Aleksandra
Director
25,000 @ ——
Grant
2025-02-05
Goldan Keith A.
Chief Financial Officer
110,500 @ $14.65$1.62M
Grant
2025-02-05
Gallagher Neil
President, Head of R&D
18,500 @ ——
Grant
2025-02-05
Gallagher Neil
President, Head of R&D
23,400 @ ——
Grant
2025-02-05
Gallagher Neil
President, Head of R&D
110,500 @ $14.65$1.62M
Grant
2025-02-05
Katkin Keith
Director
25,000 @ ——
Grant
2025-02-05
Huber Martin H. Jr.
Director
25,000 @ ——
Grant
2025-02-05
Goldan Keith A.
Chief Financial Officer
18,500 @ ——
Grant
2025-02-05
Goldan Keith A.
Chief Financial Officer
23,400 @ ——
Grant
2025-02-05
Metzger Michael A
Chief Executive Officer
60,500 @ ——
Grant
2025-02-05
Metzger Michael A
Chief Executive Officer
89,000 @ ——
← All catalysts for $SNDX